Niamh A Leonard
Overview
Explore the profile of Niamh A Leonard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leonard N, Corry S, Reidy E, Egan H, OMalley G, Thompson K, et al.
iScience
. 2024 Sep;
27(9):110701.
PMID: 39310770
CMS4 colorectal cancer (CRC), based on the consensus molecular subtype (CMS), stratifies patients with the poorest disease-free survival rates. It is characterized by a strong mesenchymal stromal cell (MSC) signature,...
2.
Egan H, Treacy O, Lynch K, Leonard N, OMalley G, Reidy E, et al.
Cell Rep
. 2023 May;
42(5):112475.
PMID: 37167967
Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppression in...
3.
Corry S, McCorry A, Lannagan T, Leonard N, Fisher N, Byrne R, et al.
Gut
. 2022 Apr;
71(12):2502-2517.
PMID: 35477539
Objective: Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy. Design: To address the lack...
4.
Leonard N, Reidy E, Thompson K, McDermott E, Peerani E, Tomas Bort E, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885111
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. CRC develops in a complex tumour microenvironment (TME) with both mesenchymal stromal cells (MSCs) and immune infiltrate, shown...
5.
Naicker S, Feerick C, Lynch K, Swan D, McEllistrim C, Henderson R, et al.
Oncoimmunology
. 2021 Feb;
10(1):1859263.
PMID: 33552684
Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone...
6.
Reidy E, Leonard N, Treacy O, Ryan A
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33435170
Although there have been many advances in recent years for the treatment of colorectal cancer (CRC), it still remains the third most common cause of cancer-related deaths worldwide. Many patients...
7.
OMalley G, Treacy O, Lynch K, Naicker S, Leonard N, Lohan P, et al.
Cancer Immunol Res
. 2018 Sep;
6(11):1426-1441.
PMID: 30228206
Stromal cells of mesenchymal origin reside below the epithelial compartment and provide structural support in the intestine. These intestinal stromal cells interact with both the epithelial cell compartments, as well...